Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive hematologic malignancy with limited therapeutic options for refractory patients.
• Current treatments for DLBCL often face challenges with efficacy and patient prognosis.

Purpose of the Study:

• To report the discovery and preclinical evaluation of golcadomide (CC-99282), a novel cereblon-modulating CELMoD agent for DLBCL treatment.
• To assess golcadomide's mechanism of action, antitumor activity, and potential as a drug candidate.

Main Methods:

• Golcadomide's degradation of IKZF1 and IKZF3 was assessed in preclinical models.
• Antitumor activity was evaluated in human lymphoma cell lines and mouse xenografts.
• Pharmacologic and CRISPR screening identified underlying genes and pathways.

Main Results:

• Golcadomide demonstrated rapid, deep, and sustained degradation of IKZF1 and IKZF3, surpassing lenalidomide's activity.
• The agent downregulated MYC, promoted apoptosis, and induced immunogenic cell death in lymphoma cells.
• Golcadomide preferentially distributed to lymphoma tissues, leading to enhanced tumor regression and tumor-free outcomes in vivo.

Conclusions:

• Golcadomide exhibits potent and broad antitumor activity against DLBCL through targeted protein degradation.
• These preclinical findings strongly support golcadomide as a promising therapeutic candidate for DLBCL, warranting further clinical investigation.